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A novel 18-amino acid deletion in apolipoprotein E associated stances in markedly dilated glomerular capillaries, dys-
with lipoprotein glomerulopathy. lipidemia, and elevated plasma levels of apolipoprotein
Background. Lipoprotein glomerulopathy (LPG) is a novel (apo) E [1, 2]. Clinically, systemic atherosclerotic compli-disease characterized by proteinuria, lipoprotein thrombi in
cations are thought to be unusual in patients with LPG,glomeruli, and an increased concentration of plasma apolipo-
whereas they commonly have dyslipidemia [3].protein (apo) E. Previous studies have shown that a genetic
disorder of apo E may be associated with the genesis of this Twenty-eight cases of LPG have been reported in the
disease. literature. Its occurrence in several families and the re-
Methods. An apo E mutation was analyzed in a 57-year-old currence in two transplanted kidneys suggest that theJapanese male with LPG and systemic atherosclerotic compli-
disease may be induced by the genomic abnormalitiescations. Apo E phenotypes were analyzed by isoelectric focus-
of lipoprotein metabolism associated with apo E. Weing and immunoblotting. Apo E genotypes were determined
by restriction fragment isotyping with HhaI. Polymerase chain have recently identified apo E variants, apo E2 (Arg
reaction (PCR) products of apo E coding region exons 3 and 145→Pro) Sendai [4] and apo E2 (Arg 25→Cys) Kyoto
4 were cloned into pT7Blue-T-vector and were sequenced.
in Japanese patients with LPG (abstract; Matsunaga etResults. A novel apo E mutation was identified in this patient
al, Circulation 98:I238, 1998), suggesting that a geneticand his family. There was a discrepancy between an apo E
phenotype (E1/3) and genotype (E3/3). Sequence analysis disorder of apo E may be implicated in the pathogenesis
showed a 54 bp deletion in exon 4 of the apo E gene, causing of LPG. We believe that characterization of apo E in
the 18-amino acid deletion (Gln 156-Gly 173→0). This deletion patients with LPG is crucial for exploring the pathogene-mutation was further confirmed by the detection of a short
sis and/or their risk for inheriting this disease. We experi-fragment of PCR-amplified DNA using polyacrylamide gel
enced a case of LPG that presented a critical atheroscle-electrophoresis. The patient was a heterozygote with apo E1,
and this mutation was determined to be the structural basis rotic complication. In this case and his kindred, we
for the apo E1 phenotype. One of two daughters was a hetero- identified a novel apo E phenotype variant and charac-
zygous carrier of apo E1, although she did not have proteinuria
terized it on a molecular basis.or atherosclerotic diseases.
Conclusions. Apo E1 (Gln 156-Gly 173→0) is a novel muta-
tion of apo E that may be etiologically related to LPG and to
METHODSthe development of atherosclerosis. The result of this family
study suggests that the occurrence of LPG may involve other Case presentation
genetic or environmental factors.
A 57-year-old Japanese man with a symptom of severe
back pain was brought to the Kidney Center at Tokyo
Women’s Medical University by ambulance on AprilLipoprotein glomerulopathy (LPG) is a new renal dis-
16th, 1994. His case was diagnosed as a rupture of anease entity that is characterized by thrombus-like sub-
abdominal aortic aneurysm (AAA) and was successfully
operated. Before this critical episode, he periodically
received examination and treatment for persistent pro-Key words: atherosclerosis, apolipoprotein E1, gene mutation, amino
acid deletion, proteinuria. teinuria, hypertension, and atherosclerotic complica-
tions. Proteinuria was found first in 1966 (30-year-old),Received for publication September 23, 1998
slowly progressed, and developed into nephrotic syn-and in revised form March 31, 1999
Accepted for publication April 8, 1999 drome in 1989 (53-year-old). The histological findings of
his renal biopsy specimen verified that nephrotic syn- 1999 by the International Society of Nephrology
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Fig. 1. (A and B) Light microscopy of a glomerulus in the biopsy specimen. Two of the 12 glomeruli in the specimen show global sclerosis. Some
nodular lesions with mesangial cell proliferation and the thickening of glomerular basement membrane are found in the remaining glomeruli.
Most of the dilated capillary lumina contain pale-staining amorphous thrombi (arrowheads) (PAM staining; A 3200 and B 3400). (C and D)
Electron microscopy. Mesangial interposition is observed (arrow in C). The capillary lumen is occupied with lipoprotein thrombi, which consist
of vacuoles with various sizes and strata as fingerprints (arrow in D). Some glomerular basement membranes are thickened and ruptured. Electron
dense deposits are seen in the subendothelial space and in the basement membrane.
drome was due to LPG (Fig. 1 A–D). The AAA was hemoglobin 7.9 g/dl, and hematocrit 24.3%. Liver func-
tion and immunologic tests were normal.found by chance in October 1990, when the patient re-
ceived an ultrasonographical examination of his kidneys.
Characterization of plasma lipids and lipoproteinsIt had enlarged up to 6.7 cm in diameter by the time of
March 1994 (Fig. 2). He had also suffered from arterio- After an overnight fast, blood was drawn from an ante-
cubital vein into tubes containing 0.1% of ethylenedi-sclerosis obliterans (ASO), but otherwise showed no par-
ticular symptoms or signs of atherosclerotic diseases. He aminetetraacetic acid-2Na. Plasma was prepared by cen-
trifugation (3000 r.p.m. for 15 min) for measurementsdid not have diabetes mellitus. On admission, physical
examination showed slight peripheral edema and the of TC and TG. Plasma concentrations of apo A-I, A-II,
B, C-II, C-III, and E were measured by single radial immu-absence of corneal arcus and xanthoma. His height was
170 cm and body weight was 68 kg. The blood pressure nodiffusion methods (Daiichi Pure Chemicals, Co., Tokyo,
Japan). Plasma lipoproteins were separated by sequen-was 150/70 mm Hg. Urine analysis showed protein excre-
tion 1.53 g/day and 8 to 10 red blood cells per high- tial ultracentrifugation. The following density fractions
were obtained: very low-density lipoprotein (VLDL; d ,powered field. Laboratory examination showed blood
urea nitrogen 19.3 mg/dl, serum creatinine 1.4 mg/dl, 1.006 g/ml), intermediate density lipoprotein (IDL; d 5
1.006 to 1.019 g/ml), low density lipoprotein (LDL; d 5creatinine clearance 56.9 ml/min, total protein 5.0 g/dl,
albumin 3.1 mg/dl, total cholesterol (TC) 166 mg/dl, tri- 1.019 to 1.063 g/ml), and high density lipoprotein (HDL;
d 5 1.063 to 1.21 g/ml). Control samples for comparingglycerides (TG) 214 mg/dl, and fasting blood glucose 107
mg/dl. Hematological examination demonstrated white plasma concentrations of lipids and lipoproteins were
obtained from age- and gender-matched healthy subjects.blood cells 14,900/mm3, red blood cells 2.69 3 106/mm3,
Ando et al: Novel apo E mutation in LPG 1319
Fig. 2. Abdominal computed tomography of the patient on March 1994. The aortic abdominal aneurysm has an intramural thrombus, and its size
is approximately 6.7 cm in diameter. The true lumen of the aorta is indicated by the arrowheads.
Analysis of apo E phenotypes by isoelectric focusing Oligonucleotide primers were synthesized based on the
and immunoblotting published manual for the DNA synthesizer (Model 380B;
Applied Biosystems, Inc., Foster City, CA, USA) usingIsoelectric focusing (IEF) was performed using poly-
the phosphoramidite method. PCR was performed usingacrylamide gels as described previously [5]. For this pur-
a modified protocol obtained from Perkin-Elmer Cetuspose, 10 ml of plasma were added to 30 ml of sialidase
Instrument Co., Ltd. (Norwalk, CT, USA). A volume ofsolution (10 mU of neuraminidase in 66 mm acetate
20 pmol of each primer was mixed in a 100 ml reactionbuffer, pH 5.0) and were incubated at 378C for two hours.
mixture consisting of 10 mm KCl, 10 mm (NH4)2SO4, 20Lipids were extracted from neuraminidase-treated sam-
mm Tris-HCl, pH 8.8, 2 mm MgSO4, 0.1% Triton X-100,ples with 1.0 ml of chilled chloroform:ethanol:ether
and 20 mm each of dATP, dCTP, dGTP, and dTTP. The(4:2:1, vol/vol/vol). Apo E phenotypes were then sepa-
mixture was then incubated at 968C for 10 minutes andrated by IEF on a 7.2% polyacrylamide gel containing
centrifuged briefly, and 2.5 units of Taq DNA polymer-5 m urea and 2% ampholytes at pH 4 to 6 and pH 5 to
ase (Perkin-Elmer Cetus) were added. The mixture was8 mixed 2:1. Finally, the phenotypes were detected by
sealed in 100 ml of mineral oil. The regions of primerimmunoblotting using goat anti-apo E antiserum (Daii-
pairs 1 (59-CTAGGTAGCTAGATGCCTGGAC-39) andchi Pure Chemicals Co.) as the primary antibody.
2 (59-AGACTTAGCGACAGGGGC-AGAATG-39) for
DNA amplification by polymerase chain reaction exon 3 and 3 (59-ATCAAGCTTTCGCCCGCCCCATC
CCAGCCC-TTC-39) and 4 (59-CGTGAATTCGCATGGGenomic DNA was isolated from 120 ml of peripheral
CTGCAGGCTTCGGCGTTC-39) for exon 4 were PCRblood as described in the Genomix kit manual (Talent
amplified as follows: denaturing at 968C for 30 seconds,srI, Milan, Italy). Ten microliters of this extract were
used as template for polymerase chain reaction (PCR). annealing at 658C for 30 seconds, and polymerization at
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728C for 1 minute for 30 cycles using a thermocycler
(Model PJ 2000; Perkin-Elmer Cetus), as described pre-
viously [6]. For the detection of short DNA fragment with
the deletion, the region of primer pairs 3 and 4 was PCR
amplified.
Determination of apo E genotypes by restriction-
fragment-length-polymorphism analysis
Genomic DNA was amplified by PCR using oligonu-
cleotide primers F4 (59-ACAGAATTCGCCCCGGCC
TGGTACAC-39) and F6 (59-TAAGCTTGGGCACGG
CTGTCCAAGGA-39), as described by Emi et al [7],
using a restriction fragment length polymorphism
(RFLP). Apo E genotypes were determined by restric-
tion fragment isotyping with HhaI as reported by Hixson
Fig. 3(A) Isoelectric focusing and immunoblot analysis for apo E. Laneand Vernier [6]. The PCR products were digested with 1, apo E2/2; lane 2, apo E3/3; lane 3, apo E4/4; and lane 4, E1/3, a
12 units of the restriction enzyme HhaI for three hours at sample of the patient. (B) Restriction-fragment-length-polymorphism
(RFLP) analysis of the apo E genotype. PCR-amplified DNA of the378C under conditions outlined by the supplier (Takara
apo E gene, including codons 112 and 158, was digested with HhaI.Biochemicals, Kyoto, Japan). Digested fragments were Lane 1, control subject with an apo E genotype e2/3. Lane 2, the patient
electrophoresed on 8% polyacrylamide gel at 200 V for with e3/3.
30 minutes. The DNA was later stained with ethidium
bromide.
DNA sequence analysis the receptor-binding domain (Fig. 5). In addition, the
mutation was further confirmed by the detection of aThe PCR-amplified DNA was isolated by electropho-
shorter fragment of PCR-amplified DNA on the 0.8%resis on a 0.8% agarose gel and ligated into pT7Blue-
polyacrylamide gel (Fig. 6).T-vector (Novagen, Madison, WI, USA), as previously
reported [8]. Twelve clones were sequenced using a 373A
Family studyautomated DNA sequencer (Applied Biosystems, Inc.).
The pedigree of the patient is illustrated in Figure 7.The nucleotide numbers are based on the published se-
The proband (the patient, I-1) and his older daughterquence for human genomic apo E DNA [9].
(II-1) was a heterozygous carrier of the same mutation.
The carrier (II-1), however, did not show any clinical
RESULTS symptoms or signs of renal and cardiovascular diseases.
Isoelectric focusing gel analysis and RFLP analysis
Lipid and lipoprotein profilesfor apo E
Plasma lipid and lipoprotein profiles of the probandPlasma apo E phenotypes were analyzed using IEF.
and his daughters are summarized in Tables 1 and 2.The patient had alleles E1/E3 (Fig. 3A). Apo E genotyp-
ing, using restriction enzyme (HhaI) digestion of DNA, The levels of plasma VLDL cholesterol, IDL cholesterol,
identified that the patient had alleles E3/3 (Fig. 3B). and TG were elevated in the proband. The proband had
There was a discrepancy between an apo E phenotype a low level of HDL cholesterol (Table 1). Apo E levels
(E1/3) and genotype (E3/3) in the patient. were remarkably high and apo A-II levels were slightly
low in both the proband and II-1 (Table 2).
DNA sequence analysis
Genomic DNA from the patient was amplified by the
DISCUSSIONPCR. PCR products of apo E coding region exons 3 and
We have demonstrated a unique apo E1 mutation in a4 from the patient were cloned into pT7Blue-T-vector
patient with LPG who concomitantly presented systemicand were sequenced. Twelve independent clones of exon
atherosclerotic diseases. DNA sequence analysis re-4 were analyzed by DNA sequencing. The sequences of
vealed that the mutation was the result of a 54 bp deletionfive clones were identical to the normal apo E3 allele,
at nucleotides 4064–4117 of apo E gene. This mutationwhereas seven clones showed a 54 bp deletion in exon
results in the 18 amino acid deletion at position 156–173,4 of the apo E gene between positions 4064 and 4117
producing apo E1 (Gln 156-Gly 173→0). In contrast to(Fig. 4). The deletion is located at the middle part of
IEF analysis of the patient’s plasma, the RFLP analysisthe helical domain and removes 18 amino acids at posi-
tions 156 to 173, which are thought to be adjacent to by HhaI for determining the apo E genotype failed to
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Fig. 4. Nucleotide sequence of part of exon
4 of both alleles of the patient. Autosomal
fluorescent sequencing was performed using
plasmid clones. The normal apo e3 allele con-
taining the sequence between positions 4064
and 4117 coding for 18 amino acids is shown
on the upper panel. The 54 bp deletion mutant
allele is shown on the lower panel.
Fig. 5. Nucleotide and amino acid sequences
across the 54 bp deletion in the mutant allele
and the corresponding normal allele.
Fig. 6. Polyacrylamide gel electrophoretic pattern of DNA fragments.
This PCR resulted in the production of a fragment, 830 bp long in
normal control. Lane M, marker from a digest of φX 174; lane 1, proband
(I-1); lane 2, normal control; lane 3, daughter (II-1); lane 4, daughter
(II-2). The proband (I-1) and the carrier (II-1) show two DNA frag- Fig. 7. Family tree of the patient with apo E1 (Gln 156-Gly 1730). The
proband (I-1) is indicated by the arrow. Symbols are (s) unaffectedments, 830 and 776 bp long, indicating that the 54 bp deletion exists in
one of the apo E alleles. female (j or d) heterozygous for the apo E1 (Gln 156-Gly 173→0).
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Table 1. Plasma lipoprotein levels of apo E1 (Gln156-Gly173→0) family
Cholesterol mg/dl
Age Triglycerides
Subjects Gender years Total VLDL IDL LDL HDL mg/dl
Carrier
I-1a Male 61 163 62.6 16.8 60 23.4 223
II-1 Female 31 167 22.3 7.6 84.2 53 49.6
Non-carrier
II-2 Female 28 175 28 15.4 83.2 48.2 65.1
Controlsb (N 5 22) 199 624.8 25.4610.4 9.8 65.2 107623.8 57.7610.9 114627.9
Abbreviations are: VLDL, very-low density lipoprotein; IDL, intermediate density lipoprotein; LDL, low density lipoprotein; HDL, high density lipoprotein.
a Indicates the proband
b Values are mean 6 sd
Table 2. Apolipoprotein concentrations and apo E isoforms of apo E1 (Gln156-Gly173→0) family
Apolipoproteins mg/dl Apo E
Age
Subjects Gender years A-I A-II B C-II C-III E Phenotype Genotype
Carrier
I-1a Male 61 102 23 99 5.2 10.8 8.2 E1/E3 E3/E3
II-1 Female 31 123 26 62 2.3 6.8 10.7 E1/E3 E3/E3
Non-carrier
II-2 Female 28 119 38 72 1.9 6.0 3.2 E3/E3 E3/E3
Controlsb (N 5 22) 150618 33.263.8 99 625.6 3.961.1 9.7 62.1 4.3 61.0
a Indicates the proband
b Values are mean 6 sd
detect the variant. The patient was thus identified as an dysbetalipoproteinemia. He had no major abnormalities
of plasma lipid profiles except for an elevated level ofapo E3/3 homozygote. Family study showed that one of
two daughters had the same apo E1 mutation, but she apo E. The 18-amino acid deletion, as described earlier
in this article, may alter the conformation of the centralhad no renal or cardiovascular diseases.
The major physiological role of apo E is to mediate the portion of apo E, which could, in part, contribute to the
occurrence and development of atherosclerosis. Furtherbinding of lipoproteins to LDL receptors and remnant
lipoprotein receptors [10]. The functions of apo E pheno- studies on the molecular function of this new apo E
variant are necessary to address this question.types are considered to be relevant to the pathogenesis
of hyperlipidemia and/or atherosclerosis [10, 11]. It was Several genomic mutations of apo E may play a pivotal
role in the pathogenesis of LPG [15]. We have identifiedsuggested that the central portion of apo E in the vicinity
of residues 136 to 160 is involved in binding of apo E apo E variants, apo E2 (Arg 145→Pro) Sendai [4] and
apo E2 (Arg 25→Cys) Kyoto in Japanese patients withto the LDL receptor [12]. This deletion is located at the
central part of the apo E containing Arg 158. Arg 158 LPG (abstract; Matsunaga et al, Circulation 98:I238,
1998). These findings suggested that a genetic disorderdoes not interact directly with the receptor, but a charge
at this position helps to maintain a conformation of the of apo E may be implicated in the pathogenesis of LPG.
Apo E mRNA has been detected in kidneys, suggestingreceptor-binding region so that apo E can effectively
interact with the LDL receptor [13]. The 18-amino acid that apo E is synthesized there [10, 16]. An entirely or
locally deformed mutant lipoprotein could serve as andeletion located in this critical site may transform the
apo E molecule, resulting in the alteration of its affinity inducer of deposits aggregated in the glomerulus. In-
deed, our previous pathological studies using electronfor LDL receptors.
It is noteworthy that the patient suffered from systemic microscopy showed that various types of lipid and lipo-
protein deposits occurred in the mesangial and subendo-atherosclerotic complications such as AAA, ASO, and
hypertension. None of the patients with LPG that were thelial areas before lipoprotein thrombi were formed
[17]. We have therefore speculated that in LPG, thereported in the literature presented atherosclerotic dis-
eases, although they usually had hyperlipidemia, includ- abnormal lipoproteins aggregated in the mesangial areas
primarily caused by the transformation of apo E contrib-ing dysbetalipoproteinemia [3, 14]. The patient had low
HDL cholesterol and high IDL cholesterol levels, which ute to the development of the intraglomerular lipopro-
tein thrombi in concert with some other glomerular dys-were not remarkable but might be partly relevant to his
atherosclerotic complications. He did not show definite functions [14, 17]. In addition, the result of this family
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Glu with type III hyperlipoproteinemia. Biochim Biophys Actastudy suggested that the occurrence of LPG may involve
1128:58–64, 1992
other genetic or environmental factors. 6. Hixson JE, Vernier DT: Restriction isotyping of human apolipo-
protein E by gene amplification and cleavage with HhaI. J LipidIn conclusion, we have demonstrated that heterozy-
Res 31:545–548, 1990gosity for apo E1 (Gln 156-Gly 173→0) is etiologically
7. Emi M, Wu LL, Robertson A, Myers RL, Hegfele RA, Williams
associated with LPG. We propose that this new apo E RR, White R, Lanlouel TM: Genotyping and sequence analysis
of apolipoprotein E isoforms. Genomics 3:373–379, 1988variant may be related not only to LPG, but also to the
8. Moriyama K, Sasaki J, Takada Y, Arakawa F, Matsunaga A,development of systemic atherosclerosis.
Ito Y, Arakawa K: Characterization of a novel variant of apolipo-
protein E. E2 Fukuoka (Arg-224Gln) in a hyperlipidemic patient
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